A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Trial Profile

A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions
  • Sponsors Cognition Therapeutics
  • Most Recent Events

    • 05 Dec 2016 Data from this trial will be presented at the 9th Clinical Trials on Alzheimer's Disease (CTAD) Meeting, as reported by a Cognition Therapeutics media release.
    • 05 Sep 2016 Status changed from recruiting to completed.
    • 14 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top